scholarly article | Q13442814 |
meta-analysis | Q815382 |
systematic review | Q1504425 |
review article | Q7318358 |
P819 | ADS bibcode | 2015PLoSO..1034104B |
P356 | DOI | 10.1371/JOURNAL.PONE.0134104 |
P932 | PMC publication ID | 4523191 |
P698 | PubMed publication ID | 26237421 |
P5875 | ResearchGate publication ID | 280643039 |
P50 | author | Davide Bolignano | Q37371425 |
Giuseppe Coppolino | Q37371444 | ||
P2093 | author name string | Anna Pisano | |
Graziella D'Arrigo | |||
P2860 | cites work | Pentoxifylline for treatment of sepsis and necrotizing enterocolitis in neonates | Q24187349 |
Estimating the mean and variance from the median, range, and the size of a sample | Q24801782 | ||
Mechanisms of anemia in CKD. | Q27693202 | ||
Measuring inconsistency in meta-analyses | Q27860655 | ||
K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification | Q29547560 | ||
Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes | Q33985838 | ||
Pentoxifylline for sickle-cell disease | Q34028684 | ||
Prevalence of anemia in chronic kidney disease in the United States | Q35083495 | ||
Impact of pentoxifylline and vitamin e on ribavirin-induced haemolytic anaemia in chronic hepatitis C patients: an egyptian survey | Q35207742 | ||
Anti-Inflammatory and Anti-Oxidative Nutrition in Hypoalbuminemic Dialysis Patients (AIONID) study: results of the pilot-feasibility, double-blind, randomized, placebo-controlled trial | Q37313722 | ||
Emerging therapies for chronic kidney disease: what is their role? | Q37489497 | ||
Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes | Q57396250 | ||
An Economic Evaluation of Erythropoiesis-Stimulating Agents in CKD | Q63681895 | ||
Role of pentoxifylline in treatment of anemic patients suffering chronic hemodialysis: a randomized clinical trial | Q83836600 | ||
Do pentoxifylline and ascorbic acid improve erythropoiesis stimulating agent resistance? | Q84620329 | ||
Pentoxifylline decreases serum levels of tumor necrosis factor alpha, interleukin 6 and C-reactive protein in hemodialysis patients: results of a randomized double-blind, controlled clinical trial | Q85035181 | ||
Evaluation of the effect of pentoxifylline on erythropoietin-resistant anemia in hemodialysis patients | Q87113230 | ||
Pentoxifylline does not alter the concentration of hepcidin in chronic kidney disease patients undergoing hemodialysis | Q87418428 | ||
Anaemia management and mortality risk in chronic kidney disease | Q38084470 | ||
Immune cell dysfunction and inflammation in end-stage renal disease | Q38090908 | ||
Pentoxifylline in heart failure: a meta-analysis of clinical trials. | Q38206557 | ||
Pentoxifylline, Ciprofloxacin and Dexamethasone Improve the Ineffective Hematopoiesis in Myelodysplastic Syndrome Patients; Malignancy | Q40702666 | ||
Effects of pentoxifylline on the haematologic status in anaemic patients with advanced renal failure | Q42473068 | ||
Pentoxifylline improves haemoglobin and interleukin-6 levels in chronic kidney disease | Q43063199 | ||
Immunomodulatory properties of pentoxifylline are mediated via adenosine-dependent pathways | Q43227039 | ||
Pentoxifylline for the treatment of hemolytic anemia in a patient who developed recurrent gastrointestinal bleeding while on continuous-flow left ventricular assist device support | Q44014831 | ||
Increased expression of erythropoiesis inhibiting cytokines (IFN-gamma, TNF-alpha, IL-10, and IL-13) by T cells in patients exhibiting a poor response to erythropoietin therapy | Q44486191 | ||
Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure | Q44948985 | ||
Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial | Q46122694 | ||
Effect of pentoxifylline on anaemia control in haemodialysis patients: retrospective observational case-control study. | Q46624708 | ||
The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients | Q47860343 | ||
A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial | Q48068592 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 8 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | anemia | Q5445 |
heterocyclic compound | Q193430 | ||
chronic renal insufficiency | Q736715 | ||
pentoxifylline | Q416331 | ||
systematic review | Q1504425 | ||
mechanism of action | Q3271540 | ||
P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
P304 | page(s) | e0134104 | |
P577 | publication date | 2015-08-03 | |
P1433 | published in | PLOS One | Q564954 |
P1476 | title | Pentoxifylline for Anemia in Chronic Kidney Disease: A Systematic Review and Meta-Analysis | |
P478 | volume | 10 |
Q90720906 | Anemia of Inflammation with An Emphasis on Chronic Kidney Disease |
Q53101230 | Association between serum hepcidin-25 and primary resistance to erythropoiesis-stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial. |
Q64889392 | Cardiovascular Event Rates Among Hemodialysis Patients Across Geographical Regions-A Snapshot From The Dialysis Outcomes and Practice Patterns Study (DOPPS). |
Q39246562 | Pentoxifylline plus ACEIs/ARBs for proteinuria and kidney function in chronic kidney disease: a meta-analysis |
Q92921916 | The Influence of Inflammation on Anemia in CKD Patients |
Q92074861 | Unraveling Cardiovascular Risk in Renal Patients: A New Take on Old Tale |